Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02064426 · ClinicalTrials.gov registry record · Phase 2

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

A Phase 2 study of Anemia and Renal Insufficiency, Chronic, sponsored by Bayer.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02064426: Completed Phase 2 study of Anemia and Renal Insufficiency, Chronic, sponsored by Bayer.

NCT02064426 is a Phase 2 study of Anemia and Renal Insufficiency, Chronic that has completed, run by Bayer. The registered enrollment target is 88 participants, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02064426, a Phase 2 study of Anemia and Renal Insufficiency, Chronic, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

Evaluate efficacy and safety up to 36 months of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta. Titration will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Planned doses include 15, 25, 50, 75, 100,and 150 mg once daily.

Conditions Studied

Anemia Renal Insufficiency, Chronic

Interventions

  • DRUG Molidustat (BAY85-3934)
  • BIOLOGICAL Epoetin alfa/beta

Study Locations (20)

California

  • - Azusa
  • - Long Beach
  • - Lynwood
  • - Northridge
  • - San Dimas
  • - Whittier
  • - Whittier

Texas

  • - Fort Worth
  • - Fort Worth
  • - Fort Worth
  • - Grand Prairie

Florida

  • - New Port Richey
  • - Pembroke Pines

Ohio

  • - Cincinnati
  • - Toledo

Michigan

  • - Detroit

Missouri

  • - Creve Coeur

New York

  • - Buffalo

Oklahoma

  • - Oklahoma City

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2014-03-13
Est. Completion 2016-11-16
Phase Phase 2
Bayer

591 total trials

What the finished NCT02064426 record still lists

NCT02064426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Molidustat (BAY85-3934) is the first listed.

NCT02064426 names 20 study sites across 9 states, led by California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT02064426 about?

NCT02064426 is a clinical study titled "Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934". Evaluate efficacy and safety up to 36 months of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta. Titration will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Planned doses include 15, 25, 50, 75, 100,and 150 mg once daily.

What is the current status of trial NCT02064426?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2014-03-13. Estimated completion is 2016-11-16.

What conditions does trial NCT02064426 study?

This clinical trial studies the following conditions: Anemia, Renal Insufficiency, Chronic.

What interventions are being tested in trial NCT02064426?

The interventions under investigation include: Molidustat (BAY85-3934) (DRUG), Epoetin alfa/beta (BIOLOGICAL).

Who is sponsoring clinical trial NCT02064426?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02064426 being conducted?

This trial has 20 study locations across California, Florida, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02064426's enrollment target sits among peer trials

88 47th of 72 higher than 26 of 72 other Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02064426, the US trial registry maintained by the National Library of Medicine. NCT02064426 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.